Ahead of US gene ther­a­py ex­plo­sion, big con­tract drug man­u­fac­tur­er Catal­ent makes $1.2 bil­lion bet on Paragon Bioser­vices

As drug de­vel­op­ers ag­gres­sive­ly pur­sue gene ther­a­pies and their mak­ers, the man­u­fac­tur­ing end of the sup­ply chain is al­so for­ti­fy­ing it­self for the wave of ther­a­pies ex­pect­ed to hit the mar­ket in the com­ing years. Less than a month af­ter Ther­mo Fish­er un­veiled a $1.7 bil­lion deal to swal­low Bram­mer Bio — a com­pa­ny that does con­tract vi­ral vec­tor man­u­fac­tur­ing for cell and gene ther­a­py de­vel­op­ers — Catal­ent is plan­ning to fork over $1.2 bil­lion for pri­vate-eq­ui­ty backed Paragon Bioser­vices.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER